Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ocular Myasthenia Gravis.

Neil C Porter1, Brian C Salter

  • 1University of Maryland School of Medicine, 22 South Green Street, Baltimore, MD 21201, USA. nport001@umaryland.edu.

Current Treatment Options in Neurology
|December 22, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Black Americans have worse stroke outcome compared with non-Hispanic whites.

Journal of the National Medical Association·2023
Same author

Racial and Ethnic Equity in Neuromuscular Care-Time for Our Action to Live Up to Potential.

JAMA neurology·2022
Same author

Review of general and head and neck/oral and maxillofacial features of Charcot-Marie-Tooth disease and dental management considerations.

Oral surgery, oral medicine, oral pathology and oral radiology·2022
Same author

A Severe Course of Relapsing-Remitting Acute-Onset Chronic Inflammatory Demyelinating Polyneuropathy in a Young Man.

Case reports in neurology·2021
Same author

Inflammatory Pseudotumor of the Temporal Bone: A Case Series.

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology·2017
Same author

Rapidly worsening bulbar symptoms in a patient with spinobulbar muscular atrophy.

Neurology international·2014
Same journal

Visual Impairment and Driving in Older Adults: A Narrative Review.

Current treatment options in neurology·2026
Same journal

Non-Cognitive Symptoms in Alzheimer's Disease and Their Likely Impact on Patient Outcomes. A Scoping Review.

Current treatment options in neurology·2026
Same journal

Update on the Treatment of Autonomic Disorders.

Current treatment options in neurology·2025
Same journal

Primary Progressive Aphasia Treatment: Current Treatment Options in Neurology Article Topic: Management of Primary Progressive Aphasia.

Current treatment options in neurology·2025
Same journal

Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).

Current treatment options in neurology·2025
Same journal

Diagnosis and Management of Progressive Corticobasal Syndrome.

Current treatment options in neurology·2025
See all related articles

Ocular myasthenia gravis (MG) affects eye muscles, causing disabling symptoms. Treatments range from acetylcholinesterase inhibitors to immunosuppressants and surgery, tailored to individual patient needs.

Area of Science:

  • Neurology
  • Immunology
  • Ophthalmology

Background:

  • Myasthenia gravis (MG) is an autoimmune disorder targeting the neuromuscular junction.
  • Ocular myasthenia gravis (ocular MG) specifically impacts eye and eyelid muscles, causing significant patient distress and disability.

Purpose of the Study:

  • To review the clinical presentation and pathological basis of ocular myasthenia gravis.
  • To outline current and alternative treatment strategies for ocular myasthenia gravis.

Main Methods:

  • Review of medical literature on ocular myasthenia gravis.
  • Analysis of treatment efficacy and safety profiles for various interventions.

Main Results:

  • Acetylcholinesterase inhibitors are first-line treatments for mild ocular MG.

Related Experiment Videos

  • Moderate to severe cases require tailored approaches including intravenous immunoglobulin, corticosteroids, or steroid-sparing agents like azathioprine.
  • Surgical options and thymectomy are considered for refractory or specific patient groups.

    • Conclusions:

    • Ocular myasthenia gravis management necessitates individualized treatment plans.
    • A combination of pharmacological and surgical interventions can effectively address symptoms and potentially alter the disease course.